CARDAX INC. CDXI overview

Cardax Reports Q3 2019 Results - CHASE clinical trial interim review demonstrated beneficial changes in markers of cardiovascular health - Composition of matter and use patents filed to extend U.S. and worldwide patent coverage to 2039-2040 - ZanthoSyn® sales rebounded -- Q3 2019 sales five times Q2 2019, with return to normal inventory sell-in patterns - $1,390,000 raised since beginning of Q3 2019 to date PR Newswire HONOLULU, Nov. 14, 2019 HONOLULU , Nov. 14, 2019 /PRNewswire/ -- Cardax,...

Cardax Announces Interim Results from CHASE Clinical Trial Pre-Specified Interim Review Demonstrated Beneficial Changes in Markers of Cardiovascular Health - CRP, LDL, total cholesterol, triglycerides, oxidized LDL, and blood pressure reduced - Interim results support excellent safety profile - Enrollment continues PR Newswire HONOLULU, Sept. 23, 2019 HONOLULU , Sept. 23, 2019 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) today announced results from the pre-specified interim review of its ongoing...

Cardax Reports Q2 2019 Results - CHASE clinical trial progressing; interim review planned for September 2019 - $1,675,000 raised since beginning of Q2 2019 - ZanthoSyn® sell-through strong; top selling antioxidant nationwide at GNC in 2019 - ZanthoSyn® sell-in down in Q2 2019 but has increased in Q3 2019 - ZanthoSyn® retail expansion beyond GNC planned PR Newswire HONOLULU, Aug. 14, 2019 HONOLULU , Aug. 14, 2019 /PRNewswire/ -- Cardax, Inc. (OTCQB:CDXI) today filed its Quarterly Report on...

Cardax Files Registration Statement for Proposed $15 Million Follow-On Offering - Maxim Group to serve as sole book running manager on a firm commitment basis - Funds to be used primarily for pharmaceutical development - Concurrent Nasdaq uplisting planned PR Newswire HONOLULU, Aug. 14, 2019 HONOLULU , Aug. 14, 2019 /PRNewswire/ -- Cardax, Inc. (OTCQB:CDXI) announced today that it filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed...

Cardax Reports Q1 2019 Results PR Newswire HONOLULU, May 17, 2019 HONOLULU , May 17, 2019 /PRNewswire/ -- Cardax, Inc. (OTCQB:CDXI) announced results for the quarter ended March 31, 2019 , in its Quarterly Report on Form 10-Q filed May 15, 2019 with the SEC. Cardax continued to make progress in Q1 2019 across its primary areas of focus: the ZanthoSyn® consumer health business, CHASE human clinical trial, and Rx development programs. ZanthoSyn® Sales : Q1 2019 represented the top performing...

Cardax Reports 2018 Results - Revenues More Than Doubled - CHASE Clinical Trial Initiated - Rx Development Plans for CDX-101 and CDX-301 Underway PR Newswire HONOLULU, March 28, 2019 HONOLULU , March 28, 2019 /PRNewswire/ -- Cardax, Inc. (OTCQB:CDXI) announced results for the year ended December 31, 2018 , in its Annual Report on Form 10-K filed today with the SEC. Highlights: ZanthoSyn® Sales . Revenues from Cardax's ZanthoSyn®, a physician recommended anti-inflammatory supplement for health...

Cardax to Present at NobleCon XV LEADING SMALL CAP/MICRO CAP CONFERENCE FEATURES >600 ATTENDEES PR Newswire HONOLULU, Jan. 25, 2019 HONOLULU , Jan. 25, 2019 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI), a life sciences company focused on inflammatory health, today announced that its CEO, David G. Watumull , will present at NobleCon XV—Noble Capital Markets' Fifteenth Annual Investor Conference at the W Hotel, Fort Lauderdale , Florida—on January 28 th at 11:30 AM Eastern Standard Time . About...

Cardax Reports Q3 2018 Results Robust ZanthoSyn® Sales Growth Continues - 102% Greater Than Q2 2018 - 71% Greater Than Q3 2017 - 129% 9-Month Sales Growth PR Newswire HONOLULU, Nov. 13, 2018 HONOLULU , Nov. 13, 2018 /PRNewswire/ -- Cardax, Inc. (OTCQB: CDXI) announced its results for the third quarter of 2018. Revenues from sales of ZanthoSyn®, its premium astaxanthin dietary supplement for inflammatory health and longevity, increased 102% from $272,049 in Q2 2018 to $549,540 in Q3 2018. Q3...